Metastatic carcinoma of the colon or rectum

Active Ingredient: Bevacizumab

Indication for Bevacizumab

Population group: only adults (18 years old or older)
Therapeutic intent: Adjunct intent

Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.

For this indication, competent medicine agencies globally authorize below treatments:

5 mg/kg or 10 mg/kg of body weight given once every 2 weeks, or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks

For:

Dosage regimens

Regimen A: Intravenous, 5 milligrams bevacizumab per kilogram of body weight, once every 2 weeks.

Regimen B: Intravenous, 10 milligrams bevacizumab per kilogram of body weight, once every 2 weeks.

Regimen C: Intravenous, 7.5 milligrams bevacizumab per kilogram of body weight, once every 3 weeks.

Regimen D: Intravenous, 15 milligrams bevacizumab per kilogram of body weight, once every 3 weeks.

Detailed description

The recommended dose of bevacizumab, administered as an intravenous infusion, is either 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks.

It is recommended that treatment be continued until progression of the underlying disease or until unacceptable toxicity.

Dosage considerations

It should not be administered as an intravenous push or bolus.

Dose reduction for adverse reactions is not recommended. If indicated, therapy should either be permanently discontinued or temporarily suspended.

Active ingredient

Bevacizumab

Bevacizumab binds to vascular endothelial growth factor (VEGF), the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour growth.

Read more about Bevacizumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.